文献速递消化系统肿瘤

表皮生长因子受体抑制剂对比贝伐珠单抗一线治疗RAS野生型转移性结直肠癌成人患者按肿瘤侧别的头对头试验疗效与安全性数据的Meta分析

A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
PubMed 文献 · Eur J Cancer · 2024-03-01

该系统综述与Meta分析纳入2015至2024年发表的8项试验共2624例患者,比较表皮生长因子受体抑制剂(EGFRIs)联合双药化疗与贝伐珠单抗联合双药化疗一线治疗RAS野生型转移性结直肠癌的疗效与安全性。左半肿瘤人群中,EGFRIs联合化疗在总生存(HR=0.80,95%CI:0.71-0.90)和客观缓解率(OR=1.61,95%CI:1.30-1.99)方面更优;右半肿瘤人群中,贝伐珠单抗联合化疗的无进展生存更优(HR=1.45,95%CI:1.19-1.78)。

要点

  • 左半RAS野生型mCRC:EGFRIs联合化疗较贝伐珠单抗联合化疗改善OS(HR=0.80,95%CI:0.71-0.90)和ORR(OR=1.61,95%CI:1.30-1.99)。
  • 右半RAS野生型mCRC:贝伐珠单抗联合化疗的PFS更优(HR=1.45,95%CI:1.19-1.78),OS、ORR及切除率无显著差异。
  • 全侧别人群中早期肿瘤缩小 favoring EGFRIs联合化疗(OR=1.72,95%CI:1.36-2.17)。

核心结论

  • 该Meta分析表明,在左半RAS野生型转移性结直肠癌患者中,一线EGFRIs联合化疗较贝伐珠单抗联合化疗带来获益。

研究设计与样本

  • 系统文献综述与Meta分析,纳入2015至2024年发表的临床试验数据,共8项试验、2624例患者;其中5项试验报告了按肿瘤侧别的结局。

主要发现

  • 左半肿瘤人群:OS的HR=0.80(95%CI:0.71-0.90),ORR的OR=1.61(95%CI:1.30-1.99),均支持EGFRIs联合化疗;PFS(HR=0.93,95%CI:0.84-1.04)和切除率(RR)无统计学显著差异。
  • 全侧别人群:结果与左半人群相似。
  • 右半肿瘤人群:PFS支持贝伐珠单抗联合化疗(HR=1.45,95%CI:1.19-1.78);OS(HR=1.17,95%CI:0.95-1.44)、ORR(OR=0.99,95%CI:0.69-1.41)和切除率(RR)无统计学显著差异。
  • 全侧别人群中早期肿瘤缩小支持EGFRIs联合化疗(OR=1.72,95%CI:1.36-2.17);按侧别评估受限于数据不足。
  • 安全性数据来自6项全侧别肿瘤试验和1项左半肿瘤试验,各试验均显示典型的类别特异性不良事件。

局限性

  • 按肿瘤侧别评估早期肿瘤缩小受限于数据不足。
  • 安全性数据仅来自6项全侧别肿瘤试验和1项左半肿瘤试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The first-line treatment choice of EGFRIs plus doublet chemotherapy vs. bevacizumab plus doublet chemotherapy remains a topic of interest for patients with left-sided RAS WT mCRC. We conducted a systematic literature review and meta-analysis of clinical trial data published between 2015 and 2024. We evaluated the relative efficacy and safety of first-line EGFRIs plus doublet chemotherapy (FOLFIRI or FOLFOX) vs. bevacizumab plus doublet chemotherapy for patients with RAS WT left-sided mCRC, as well as in all- and right-sided tumors. We identified eight trials with 2624 patients. Five trials reported outcomes by tumor sidedness. In the left-sided population, overall survival (OS) (Hazard Ratio (HR) = 0.80, 95% Confidence Interval (CI): 0.71-0.90) and objective response rate (ORR) (Odds ratio [OR]=1.61, 95% CI: 1.30-1.99) favored EGFRI plus chemotherapy, while no statistically significant differences were observed for progression-free survival (PFS) (HR=0.93, 95% CI: 0.84-1.04) or resection rate (RR). Similar results were found in the all-sided population. In the right-sided population, PFS favored bevacizumab plus chemotherapy (HR=1.45, 95% CI: 1.19-1.78), while no statistically significant differences were observed for OS (HR=1.17, 95% CI: 0.95-1.44), ORR (OR=0.99, 95% CI: 0.69-1.41), and RR. Early tumor shrinkage in the all-sided population favored EGFRI plus chemotherapy (OR=1.72; 95% CI: 1.36-2.17); limited data precluded evaluation by sidedness. Safety was available in 6 trials for all-sided tumors and 1 trial for left-sided tumors, each demonstrating typical class-specific adverse events. This most comprehensive meta-analysis indicates a benefit for first-line EGFRI plus chemotherapy over bevacizumab plus chemotherapy in patients with left-sided RAS WT mCRC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Yoshino T, Hooda N, Younan D, et al. A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. Eur J Cancer. 2024. PMID: 38442645. doi:10.1016/j.ejca.2024.113975

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。